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Abstract
We raised a strain of Leishmania donovani in the laboratory that was resistant to 500 nM taxol. The IC50 of the wild-type
strain for taxol was 35 nM and that of the taxol-resistant strain (T-500) was 1 WM. The T-500 strain exhibited a Mdr
phenotype; it was also resistant to other unrelated drugs like vinblastine, adriamycin and the commonly used antimonial drugs
pentostam and glucantime. Verapamil (20 nM), a calcium channel blocker, was found to reverse the resistance of T-500 to
taxol. Acquired resistance to taxol has been reported to be mediated by alterations involving tubulin in cancer cells. Thus
polymerisation assays with tubulin fractions in wild-type versus taxol-resistant cells (T-500) were performed in vitro. The
tubulin fraction from T-500 was more resistant to in vitro polymerisation than the tubulin isolated from the wild-type,
suggesting that this is one means by which the parasite may acquire resistance to taxol. ß 1999 Federation of European
Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Drug resistance is a common obstacle to chemo-
therapy and cure of diseases. Parasites like Leishma-
nia are rapidly becoming refractory to commonly
used antimonial drugs, leading to an urgent need
for novel chemotherapeutic strategies against this
disease. But in addition to developing novel chemo-
therapeutics, there is also a need to explore possible
mechanisms of resistance occurring in Leishmania
and means to circumvent it.
Taxol is a plant alkaloid that has antimitotic ac-
tivity and appears to stabilise microtubules [1,2].
Earlier reports have shown that taxol is e¡ective in
blocking the replication of Trypanosoma cruzi
parasites and is also e¡ective against drug-resistant
Trypanosoma strains [3]. We have reported earlier
that taxol at nanomolar concentrations selectively
inhibits proliferation of Leishmania donovani pro-
mastigotes as well as amastigote multiplication with-
in J774A.1 macrophages in vitro. In this study, var-
iants of this parasite resistant to taxol have been
characterised.
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2. Materials and methods
2.1. Chemicals and parasite
Powdered medium M-199 was purchased from
Sigma Chemical Co., St. Louis, MO, USA. Minimal
essential medium with alpha modi¢cation (K-MEM)
was procured from Gibco, USA. Foetal calf serum
(FCS) was obtained from Biological Industries, Isra-
el. The drugs taxol, adriamycin (doxorubicin), vin-
blastine and verapamil were also obtained from Sig-
ma Chemical Co. Pentostam and glucantime were
from Wellcome, UK and Specia, France respectively.
Freshly transformed promastigotes of L. donovani
(strain AG83) (MHOM/IN/1983/AG83) [4] were
used for raising the resistant strain. Parasites were
suspended in minimal essential medium (K-MEM)
prior to their use in the drug studies.
2.2. Selection of Leishmania variants resistant to
taxol
Promastigotes of L. donovani (strain AG83) were
made resistant to taxol by gradual increase in the
concentration of the drug as described by Coderre
et al., 1983 [5]. Wild-type cells were gradually accli-
matised to growth in increasing concentrations of the
inhibitor. The doses used for the selection procedure
were 35 nM, 50 nM, 100 nM, 150 nM, 250 nM, 350
nM, 450 nM and 500 nM. The cells were maintained
in each concentration of taxol until their growth rate
reached that of the control group. The entire selec-
tion procedure took about 3 months. All the studies
in this paper were done using the T-500 strain that
was resistant to 500 nM taxol.
2.3. Drug studies
The e¡ective concentration of the drug which in-
hibited the growth of the cells by 50% (IC50) was
determined for the wild-type and taxol-resistant cells
(T-500) at the late exponential growth phase of the
cells [6]. Verapamil was used to check if it could
render the T-500 cell line sensitive to taxol [7]. The
wild-type and T-500 cells were simultaneously incu-
bated with 20 nM verapamil and varying concentra-
tions of taxol. Verapamil (20 nM) by itself had a
marginal inhibitory e¡ect on promastigote growth.
2.4. E¡ect of taxol on leishmanial tubulin assembly in
vitro in wild-type versus taxol-resistant cells
AG83 and T-500 promastigotes were harvested
from 200-ml cultures each, washed with PBS and
re-suspended in phosphate glutamate bu¡er (PG:
20 mM NaHPO4, 100 mM glutamic acid, 1 mM L-
mercaptoethanol, adjusted to pH 7.0 with 1 mM
NaOH), PMSF (10 Wg ml31) and Triton X-100
(0.5% w/v) were added to the PG bu¡er and the cells
were homogenised. Detergent-insoluble cytoskeleton
was collected, washed in PG-PMSF (3U), frozen in
liquid nitrogen and stored at 370‡C according to the
method of Chan and Fong [8]. The pellet was thawed
on ice and resuspended in 1 ml MEMED bu¡er (100
mM MES pH 6.7, 1 mM EGTA, 1 mM MgSO4,
1 mM EDTA and 1 mM DTT). GTP (2 mM),
EGTA (1 mM) and MgCl2 (1 mM) were added to
the above solution and it was sonicated (7U20 s) to
release the cytoskeletal proteins with 1 min cooling
on ice after each sonication and a liquid nitrogen
freeze-thaw after the third sonication. The solution
was centrifuged and the supernatant was collected. It
was assayed for protein using the micro Lowry meth-
od [9]. Microtubule polymerisation was measured in
vitro in both strains. The e¡ect of di¡erent concen-
trations of taxol on tubulin assembly in both the
wild-type and T-500 strains was measured in vitro.
The tubulin samples were incubated with di¡erent
concentrations of taxol and the absorbance was
measured in a temperature-controlled spectropho-
tometer at 37‡C [2,3,10]. The absorbance was meas-
ured at 30-s intervals for a period of 1 min. Since the
maximum assembly was observed within 30 s, the
absorbance value at the 30-s time point was used
for making the graph.
3. Results
Taxol-resistant Leishmania were raised by stepwise
selection of the wild-type cells in gradually increasing
concentrations of taxol until the cells were resistant
to 500 nM taxol. This selection procedure took
about 3 months. As shown in Fig. 1, the T-500 cell
line was approximately 30-fold more resistant to tax-
ol than the wild-type strain.
We tested T-500 for resistance to adriamycin and
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found it to be 2-fold more resistant (IC50 5.0 WM)
than the wild-type parental strain (IC50 2.5 WM).
Moreover, T-500 cells were also 5-fold more resistant
to vinblastine (IC50 10.0 WM) than the wild-type
(IC50 2.0 WM). These cells were also found to be
2-fold and 5-fold more resistant respectively to pen-
tostam (IC50 0.05 mg ml31) and glucantime (IC50 2.5
mg ml31), the drugs commonly used for treating
leishmaniasis. The IC50 values for the wild-type cells
to pentostam and glucantime were 0.025 mg ml31
and 0.5 mg ml31 respectively. The resistance exhib-
ited by T-500 to unrelated drugs suggested that the
T-500 cell line exhibited a multidrug-resistant
(MDR) phenotype.
Some calcium channel blockers, such as verapamil
[7,11], can reverse multidrug resistance mediated by
P-glycoprotein. The e¡ect of verapamil was therefore
tested in the wild-type and T-500 cell lines. Verapa-
mil (20 nM) by itself resulted in marginal growth
inhibition in both wild-type and T-500 strains. After
plating 1U106 promastigotes ml31 for 24 h in K-
MEM media, verapamil (20 nM) and di¡erent con-
centrations of taxol were added to the media con-
taining promastigotes. The cells were harvested 48 h
later and counted using a Neubauer haemocytome-
ter. Di¡erent concentrations of taxol (10^30 nM)
had no e¡ect on the growth of T-500 promastigotes
in the absence of verapamil (Fig. 2). In the presence
Fig. 1. E¡ect of di¡erent concentrations of the anti-microtubule
agent taxol on the growth of wild-type (W) and taxol-resistant L.
donovani promastigotes (T-500). These results are representative
of triplicate samples.
Fig. 2. Combined growth inhibitory e¡ect of verapamil (20 nM)
and di¡erent concentrations of taxol on wild-type (W) (A) and
taxol-resistant promastigotes (T-500) (B). These results are repre-
sentative of triplicate samples.
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of verapamil, however, there was a highly signi¢cant
inhibitory e¡ect of these concentrations of taxol on
the growth of the T-500 strain (Fig. 2B). In the case
of the wild-type AG83 strain, taxol resulted in a
dose-dependent inhibition of promastigotes in the
absence of verapamil. Addition of 20 nM verapamil
did not alter the inhibitory e¡ect of taxol on pro-
mastigote growth (Fig. 2A).
In order to check if acquired resistance to taxol
can be mediated by alterations involving tubulin,
tubulin was isolated from wild-type and T-500 cells
and its polymerisation pattern in these two cell types
was studied in the presence of di¡erent concentra-
tions of taxol. Fig. 3 shows the comparative assem-
bly patterns of tubulin from wild-type and T-500
leishmanial promastigotes in the presence of di¡erent
concentrations of taxol. The concentration of tubulin
used for the polymerisation experiment with the
wild-type strain was 1 mg ml31 and for the T-500
strain it was 2 mg ml31. The above two tubulin
concentrations were chosen after preliminary poly-
merisation experiments were performed with tubulin
from wild-type and T-500 cells in the absence of
taxol. These preliminary results showed that there
was an approximately comparable polymerisation
at these two concentrations of tubulin.
The comparative assembly patterns of tubulin
from wild-type and T-500 leishmanial cells using
1 mg ml31 and 2 mg ml31 of tubulin respectively
showed that T-500 tubulin requires a much higher
concentration of taxol for its polymerisation as com-
pared to the wild-type strain. These results show that
acquired resistance to taxol in the T-500 strain is
probably due to resistance to polymerisation by tax-
ol in this strain, which may be due to alterations in
the tubulin of the T-500 strain.
4. Discussion
Drug resistance is a common obstacle to leishma-
nial therapy today. The inability of currently used
drugs to control Leishmania, on account of the
widely increasing incidence of drug-resistant organ-
isms, makes it necessary not only to devise alterna-
tive chemotherapeutic strategies but also to explore
the mechanisms by which the parasite becomes re-
sistant to di¡erent drugs.
The mechanism by which L. donovani could be-
come resistant to taxol was explored. A taxol-resist-
ant L. donovani cell line (T-500) exhibited cross-re-
sistance to several unrelated drugs like adriamycin,
vinblastine and the antimonial compounds pentos-
tam and glucantime indicating that T-500 had an
MDR phenotype. Gueiros-Filho et al. [7] have
shown that the MDR phenotype can be reversed
by the calcium channel antagonist verapamil, a fea-
ture that was also found in the T-500 cell line. More-
over, in the case of the wild-type strain, it was ob-
served that there was absence of enhancement of
inhibition with verapamil, indicating the absence of
any synergistic inhibition e¡ect of verapamil in com-
Fig. 3. E¡ect of taxol on microtubule assembly in vitro in wild-
type (W) and taxol0resistant (T-500) cells. L. donovani tubulin
was prepared as described and analysed in Section 2.
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bination with taxol. However, hybridisation studies
with a mammalian mdr probe showed that taxol-re-
sistant cells did not contain ampli¢ed MDR DNA
(data not shown), suggesting that resistance to taxol
may be mediated by some mechanism other than
ampli¢cation of the gene encoding the mammalian
MDR phenotype.
Multidrug resistance does not necessarily require
gene ampli¢cation. Increased expression of the multi-
drug gene without MDR gene ampli¢cation is com-
monly observed in di¡erent types of cancers and ap-
pears to be a signi¢cant marker of clinical drug
resistance [12]. It is possible that this mechanism
may be involved in resistance to taxol in L. donovani.
There are other mechanisms involved in resistance
to taxol. Acquired resistance to paclitaxel can be
mediated by P- glycoprotein or by alterations involv-
ing tubulin. The latter is observed in taxol-resistant
cell lines derived from 1A9 human ovarian carcino-
ma cells [13]. No MDR-1 mRNA can be detected in
these cells. The total tubulin content in taxol-sensi-
tive and -resistant cells remains the same but the
polymerised fraction increases in wild-type cells as
compared to resistant cells following taxol addition.
The present in vitro tubulin polymerisation studies
of wild-type and taxol-resistant leishmanial cells with
taxol showed that T-500 cells are indeed more resist-
ant to polymerisation with taxol. The taxol concen-
trations needed to cause the same degree of polymer-
isation in T-500 cells were much higher as compared
to the wild-type cells. However, whether the exact
mechanism involved is mutation or change in the
tubulin isotype still remains to be explored.
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